A promising therapeutic approach being studied uses IGF-1 analogues such as PEG-IGF-1 [263], which offers promising protection against acute contraction-induced muscle injury
TB-500 is dosed less frequently, typically once or twice per week during a loading phase and once every two weeks during maintenance, reflecting its longer half-life and systemic distribution pattern
TB-500 can be administered at any time without affecting systemic absorption, tissue distribution, or regenerative capacity
Carcel reports being supported by the Australian Heart Foundation Postdoctoral Fellowship (102741) and an Australian National Health and Medical Research Council (NHMRC) Investigator Grant, Emerging Leadership 1 (APP2009726)
Therefore after evaluation of antibody levels, the EMN recommends the following as it pertains to patients that have not responded: These patients should receive an additional dose of vaccine These patients should continue to physically distance and reduce their risk of infection These patients should ensure that their carers and close contacts are all vaccinated These patients may require monoclonal antibodies if they come into contact with or have been exposed to someone with COVID-19 Given your immunocompromised state, it is important that those around you, especially your carers, receive their COVID-19 vaccine
